Final Results of a Phase I/II Trial of the Combination of Concurrent Lenalidomide, Thalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Myeloma

被引：2
|
作者：
Shah, Jatin J. [1 ]
Orlowski, Robert Z. [1 ]
Thomas, Sheeba K. [1 ]
Alexanian, Raymond [1 ]
Wang, Michael
Qazilbash, Muzaffar H. [2 ]
Popat, Uday R. [3 ]
Parmar, Simrit
Shah, Nina
Bashir, Qaiser
Champlin, Richard E. [3 ]
Weber, Donna M. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX 77030 USA
[2] UT MD Anderson Canc Ctr, SCT CT Unit 423, Houston, TX USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX USA
来源：
BLOOD | 2012年 / 120卷 / 21期
关键词：
D O I：
10.1182/blood.V120.21.75.75
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
75
引用
收藏
页数：2
相关论文
共 50 条
  • [1] A phase I/II trial of the combination of lenalidomide, thalidomide and dexamethasone in relapsed and/or refractory multiple myeloma
    Lee, Hans C.
    Shah, Jatin J.
    Feng, Lei
    Morphey, Ashley
    Johnson, Ralph J.
    Wesson, Emily T.
    Wang, Michael L.
    Alexanian, Raymond
    Thomas, Sheeba K.
    Orlowski, Robert Z.
    Weber, Donna M.
    AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 (12) : E319 - E322
  • [2] Phase I Trial of the Combination of Lenalidomide, Thalidomide and Dexamethasone In Relapsed/Refractory Multiple Myeloma
    Shah, Jatin J.
    Orlowski, Robert Z.
    Alexanian, Raymond
    Wang, Michael
    Thomas, Sheeba
    Qazilbash, Muzaffar H.
    Parmar, Simrit
    Shah, Nina
    Bashir, Qaiser
    Popat, Uday
    Weber, Donna
    BLOOD, 2010, 116 (21) : 811 - 812
  • [3] Final Phase I Results of Perifosine In Combination with Lenalidomide and Dexamethasone In Patients with Relapsed or Refractory Multiple Myeloma (MM)
    Jakubowiak, Andrzej J.
    Richardson, Paul G.
    Zimmerman, Todd M.
    Alsina, Melissa
    Kaufman, Jonathan L.
    Kandarpa, Malathi
    Harvey, Colleen K.
    Colson, Kathleen
    Mitchell, Monica
    Hideshima, Teru
    Sportelli, Peter
    Gardner, Lesa
    Giusti, Kathy
    Anderson, Kenneth C.
    BLOOD, 2010, 116 (21) : 1264 - 1264
  • [4] Ibrutinib, lenalidomide and dexamethasone in patients with relapsed and/or refractory multiple myeloma: Phase I trial results
    Ailawadhi, Sikander
    Parrondo, Ricardo D.
    Moustafa, Muhamad Alhaj
    LaPlant, Betsy R.
    Alegria, Victoria
    Chapin, Dustin
    Roy, Vivek
    Sher, Taimur
    Paulus, Aneel
    Chanan-Khan, Asher A.
    HEMATOLOGICAL ONCOLOGY, 2022, 40 (04) : 695 - 703
  • [5] A phase I/II trial of the combination of romidepsin and lenalidomide in patients with relapsed/refractory lymphoma and myeloma: Phase I results.
    Lunning, Matthew Alexander
    Ruan, Jia
    Nair, Sumithra
    Boruchov, Adam M.
    Byrne, Regina
    Gerecitano, John F.
    Hamlin, Paul A.
    Inserra, Beth
    Leonard, John
    Lynch, Peggy
    Matasar, Matthew J.
    Moskowitz, Alison J.
    Moskowitz, Craig
    Myskowski, Patricia L.
    Nolan, Patrick
    Palomba, Maria Lia
    Quefeld, Christiane
    Straus, David J.
    Zelenetz, Andrew David
    Horwitz, Steven M.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [6] Final Results of a Phase II Trial with Plitidepsin (Aplidin) Alone and in Combination with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
    Mateos, Maria-Victoria
    Cibeira, Teresa
    Richardson, Paul
    Blade, Joan
    Prosper, Felipe
    Oriol, Albert
    de la Rubia, Javier
    Alegre, Adrian
    Lahuerta, Juan Jose
    Garcia-Sanz, Ramon
    Mitsiades, Constantine S.
    Espinoza, Jose
    Anderson, Kenneth C.
    Miguel, J. F. San
    BLOOD, 2008, 112 (11) : 1268 - 1268
  • [7] Phase I Trial of Perifosine, Lenalidomide, and Dexamethasone in Relapsed or Refractory Myeloma
    Jakubowiak, A. J.
    Hideshima, T.
    Sportelli, P.
    Gardner, L.
    Giusti, K.
    Richardson, P. G.
    Zimmerman, T.
    Alsina, M.
    Kaufman, J.
    Brozo, C.
    Kendall, T.
    McAllister, A.
    Harvey, C.
    Anderson, K. C.
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S56 - S57
  • [8] Ixazomib in Combination With Thalidomide and Dexamethasone as Treatment for Patients With Relapsed/Refractory Multiple Myeloma: An Ongoing Phase II Trial
    Ludwig, Heinz
    Lechner, Daniel
    Gunsilius, Eberhard
    Fridrik, Michael
    Petzer, Andreas
    Kuehr, Thomas
    Knop, Stefan
    Schreder, Martin
    Weisel, Katja
    Rauch, Elisabeth
    Poenisch, Wolfram
    Greil, Richard
    Zojer, Niklas
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E75 - E75
  • [9] Dasatinib in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma: Preliminary Results of a Phase I Study
    Facon, Thierry
    Leleu, Xavier
    Stewart, A. Keith
    Spencer, Andrew
    Rowlings, Philip
    Hulin, Cyrille
    Attal, Michel
    Garzon, Felix
    Bleickardt, Eric
    Gialelis, Konstantina
    Tuozzoli, Doreen
    Derreumaux, Dorninique
    Sonneveld, Pieter
    BLOOD, 2009, 114 (22) : 744 - 745
  • [10] Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma: A phase I study
    Siegel, D. S.
    Weber, D. M.
    Mitsiades, C. S.
    Dimopoulos, M. A.
    Harousseau, J. L.
    Rizvi, S.
    Howe, J.
    Reiser, D.
    Anderson, K. C.
    Richardson, P. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345